The role of renin-angiotensin system in cardiovascular prevention

Chairpersons:
G. Mancia (Milan, Italy)
P. Zimmet (Melbourne, Australia)

Cardiovascular prevention in clinical practice - current situation and future perspectives
M. Volpe (Rome, Italy)

The role of ACE inhibition in the prevention of cardiovascular disease
S. Taddei (Pisa, Italy)

Cardiovascular prevention in patients with the metabolic syndrome
P. Zimmet (Melbourne, Australia)

Prevention of hypertension in patients at risk - is it achievable?
P. Dominiak (Lübeck, Germany)

Microalbuminuria as a predictor of cardiovascular events in patients with hypertension - the effects of ramipril
J. Schrader (Cloppenburg, Germany)

The IMPROVE study - adding irbesartan to ramipril to reduce microalbuminuria and decrease the risk of cardiovascular disease
M. Weber (New York, NY, USA)
**Treating hypertension in diabetic patients**

**Chairpersons:**

G. Mancia *(Milan, Italy)*
J. Redon *(Valencia, Spain)*

**Opening remarks**

G. Mancia *(Milan, Italy)*

**Debate on treating hypertension in diabetic patients**

**Specific drugs offer substantial added value**

D.L. Clement *(Gent, Belgium)*

**Reaching BP goal is more important than specific therapy**

F. Messerli *(New York, NY, USA)*

**Discussion**

**Lercanidipine as first line treatment in high risk subjects**

V. Barrios *(Madrid, Spain)*

**Lercanidipine as add-on therapy in diabetic patients**

H. Haller *(Hannover, Germany)*

**Is there any additional effect beyond BP control with lercanidipine in the diabetic patient?**

C. Borghi *(Bologna, Italy)*

**Closing remarks**

J. Redon *(Valencia, Spain)*
Blood pressure control and beyond: end organ protection with Eprosartan?

Chairpersons:
L.M. Ruilope (Madrid, Spain)
P. Blankestijn (Utrecht, The Netherlands)

Secondary prevention of stroke. Cerebroprotection with Eprosartan? Principal results of the MOSES study
J. Schrader (Cloppenburg, Germany)

Effects of Eprosartan on pulse pressure
A. de la Sierra (Barcelona, Spain)

Effects of Eprosartan in chronic kidney disease
P. Blankestijn (Utrecht, The Netherlands)

Does the clinical and therapeutic profile of Eprosartan contribute to end organ protection?
V. Ram (Dallas, TX, USA)
The evolution of Angiotensin Receptor Blockade: more patients, better control, vascular benefits

Chairpersons:  
S. Erdine (Istanbul, Turkey)  
S.E. Kjeldsen (Oslo, Norway)

Introduction  
S. Erdine (Istanbul, Turkey)

Response to angiotensin II blockade in the elderly  
J.M. Mallion (Grenoble, France)

Achieving BP goals: the need for effective combination therapy  
L. Rump (Bochum, Germany)

More than BP control: what else can be expected from the ARBs?  
L.M. Ruilope (Madrid, Spain)

Optimal use of angiotensin receptor blockers  
A.M. Heagerty (Manchester, UK)

Closing remarks  
S.E. Kjeldsen (Oslo, Norway)
The increasing incidence of cardiovascular disease: new paradigms for improved risk factor management

Chairpersons:
G. Mancia (Milan, Italy)
P. Sever (London, UK)

Introduction
G. Mancia (Milan, Italy), P. Sever (London, UK)

Population trends in cardiovascular risk factors: new insights
S. MacMahon (Sydney, Australia)

What impact do increasing cardiovascular risk factors have on global cardiovascular event rates?
A. Lopez (Brisbane, Australia)

Managing cardiovascular risk: what’s going wrong?
G. Mancia (Milan, Italy)

Panel discussion

How much can early/aggressive risk factor management decrease events?
J. Staessen (Leuven, Belgium)

When is it cost-effective to treat cardiovascular risk factors?
B. Jönsson (Stockholm, Sweden)

How can we optimize cardiovascular risk management? Evidence from recent clinical trials
B. Williams (Leicester, UK)

Panel discussion and chair’s summary

Close
Angiotensin receptor blockers in hypertension and heart failure - do the differences matter?

Chaipersons:
P. Meredith (Glasgow, UK)
R. McKelvie (Hamilton, ONT, Canada)

Importance of the renin-angiotensin system in the progression from hypertension to heart failure
G. Nickenig (Hamburg, Germany)

Pharmacological aspects of effective blockade of the renin-angiotensin system
T. Unger (Berlin, Germany)

Current aspects on angiotensin receptor blockade in hypertension
P. Meredith (Glasgow, UK)

Evidence base for angiotensin receptor blockade in chronic heart failure
R. McKelvie (Hamilton, ONT, Canada)
Hypertension at the intersection of diabetes, obesity and renal failure

Chairpersons:
E. Agabiti Rosei (Brescia, Italy)
L.M. Ruilope (Madrid, Spain)

Welcome and introduction
E. Agabiti Rosei (Brescia, Italy)
L.M. Ruilope (Madrid, Spain)

Early morning blood pressure surge: the culprit for lack of blood pressure control
W.B. White (Farmington, NM, USA)

The rationale for angiotensin blockade in the management of obese hypertensives
A.M. Sharma (Hamilton, ONT, Canada)

Hypertension, diabetes and renal disease - how to tackle this unholy alliance?
R.E. Schmieder (Erlangen, Germany)

Do different drugs have different cardiovascular effects in high-risk patients?
E. Agabiti Rosei (Brescia, Italy)

Questions and closing remarks
E. Agabiti Rosei (Brescia, Italy)
L.M. Ruilope (Madrid, Spain)
A straightforward strategy for all grades of hypertension

Chairpersons:
G. Mancia (Milan, Italy)
L.M. Ruilope (Madrid, Spain)

Introduction
G. Mancia (Milan, Italy)

Managing hypertension: a question of STRATHE
F. Zannad (Dommartin, France)

Further evidence for low-dose combination in patients with LVH
B. Dahlöf (Göteborg, Sweden)

Challenging established hypertension management strategies in diabetic patients
C.E. Mogensen (Aarhus, Denmark)

Targeting endothelial dysfunction in hypertensive patients
C. Thuillez (Rouen, France)

What will the ADVANCE trial tell us that we don’t already know?
N. Poulter (London, UK)

Conclusion
L.M. Ruilope (Madrid, Spain)
Are there really benefits beyond blood pressure control?

Chairpersons:
M. Volpe (Rome, Italy)
B. Williams (Leicester, UK)

Welcome and introduction: is hypertension treatment just about blood pressure lowering?
B. Williams (Leicester, UK)

Point: analysis of hypertension endpoint trials suggests blood pressure reduction is the primary driver for outcomes benefits
M. Volpe (Rome, Italy)

Counterpoint: new evidence showing benefits beyond blood pressure reduction: LIFE
B. Dahlöf (Göteborg, Sweden)

Expert panel discussion: where does the evidence lead us?
R. Devereux (New York, NY, USA)
C. Ferrario (Winston-Salem, NC, USA)
H. Ibsen (Glostrup, Denmark)

Question and answer session

Summary and closing remarks
The case for ARBs across the CV continuum - an evidence-based approach

Chairpersons:
H.A.J. Struijker-Boudier (Maastricht, The Netherlands)
A. Zanchetti (Milan, Italy)

Welcome
A. Zanchetti (Milan, Italy)

Laying the foundation: the science behind CV benefits of ARBs
G. Nickenig (Hamburg, Germany)

Targeting hypertension: VAST evidence of powerful BP reduction
L.M. Ruilope (Madrid, Spain)

Targeting CV disease: VALIANT benefits in heart failure and post MI
E.J. Velazquez (Durham, NC, USA)

Targeting risk: the physician as NAVIGATOR across the CV continuum
G.T. McInnes (Glasgow, UK)

Questions & answers
H.A.J. Struijker-Boudier (Maastricht, The Netherlands)

Session close
A. Zanchetti (Milan, Italy)
Nifedipine GITS in ACTION - a tale of two targets

Chairpersons:
G. Mancia (Milan, Italy)
P. Poole-Wilson (London, UK)

Welcome and introductory remarks: Vascular protection and hypertension - the two targets of nifedipine GITS
G. Mancia (Milan, Italy)

Taking further ACTION to improve and prevent cardiovascular disease
P. Poole-Wilson (London, UK)

Hypertension and beyond - demonstrating greater patient benefits in ACTION

Optimising blood pressure control offers clear outcome benefits
A.M. Heagerty (Manchester, UK)

Diabetes in ACTION - improving treatment and stopping progression
N. Danchin (Paris, France)

Preserving renal function - evidence in ACTION
L.M. Ruilope (Madrid, Spain)

Targeting the vascular endothelium along the CVD continuum - evidence supporting early intervention
H. Haller (Hannover, Germany)

Panel Discussion
CVD interventions - when is it too early and can we ever too much?
chaired by G. Mancia (Milan, Italy)

Closing Remarks
Closer to the heart: BP control and end organ protection

Chairperson: 
**M. Volpe (Rome, Italy)**

Opening remarks
M. Volpe (Rome, Italy)

Combination therapy and the potential for BP control and reducing CV events
R. Asmar (Paris, France)

Question and answer period

Strategies to expand organ protection properties of RAAS blocking agents
H.H. Parving (Gentofte, Denmark)

Question and answer period

Cardiac protection with RAAS blocking agents: a view from atria to ventricles
C. Moro (Madrid, Spain)

Question and answer period

Summary & Close
Pharmacological modulation of the renin-angiotensin system in hypertension: making the right choice

Chairpersons:
P. Hamet (Montreal, Canada)
S. Laurent (Paris, France)

Introduction
S. Laurent (Paris, France)

Renin-angiotensin system modulation: the weight of evidence
A. Hall (Leeds, UK)

How to explain the differences between renin-angiotensin system modulators
B. Levy (Paris, France)

Specific properties and effects of perindopril in controlling the renin-angiotensin system
R. Ferrari (Ferrara, Italy)

Evidence for benefits of perindopril in hypertension and its complications
S. Laurent (Paris, France)

Conclusion
P. Hamet (Montreal, Canada)
Renin inhibition: the key to optimizing RAS suppression for BP control and beyond

Chairpersons:
G. Mancia (Milan, Italy)
A.H. Gradman (Pittsburgh, PA, USA)

Introduction
G. Mancia (Milan, Italy)

Growing burden of disease management in the comorbid patient
G. Mancia (Milan, Italy)

RAS suppression: the right track to controlling blood pressure and preventing end-organ damage
L.M. Ruilope (Madrid, Spain)

Elevated plasma renin activity and its effects on blood pressure control and end-organ damage
J. Danser (Rotterdam, The Netherlands)

Optimized RAS suppression: preclinical experience with renin inhibition
H. Haller (Hannover, Germany)

Optimized RAS suppression in patients: experience with Aliskiren
A. Gradman (Pittsburgh, PA, USA)